BIOGEN INC
For the period ended Jun 30, 2024. Filed Aug 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 1, 2024
BIIB$254.87+2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits listed below are filed or furnished as part of this Quarterly Report on Form 10-Q.
EXHIBIT INDEX
| ExhibitNumber | Description of Exhibit |
| 4.1 | Amended and Restated Certificate of Incorporation, as amended. Incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012. |
| 4.2 | Certificate of Amendment to the Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on March 27, 2015. |
| 4.3 | Certificate of Amendment of Biogen Inc.’s Amended and Restated Certificate of Incorporation, as amended. Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 8, 2021. |
| 4.4 | Certificate of Amendment of Biogen Inc.’s Amended and Restated Certificate of Incorporation, as amended. Incorporated by reference to Exhibit 4.4 to the Registrant’s Registration Statement on Form S-8 filed on June 20, 2024. |
| 4.5 | Fifth Amended and Restated Bylaws. Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on December 12, 2023. |
| 10.1* | Biogen Inc. 2024 Omnibus Equity Plan. Filed as Appendix C to Biogen’s Definitive Proxy Statement on Schedule 14A filed on April 26, 2024. |
| 10.2* | Biogen Inc. 2024 Employee Stock Purchase Plan. Filed as Appendix D to Biogen’s Definitive Proxy Statement on Schedule 14A filed on April 26, 2024. |
| 10.3+* | Form of performance share award agreement under the Biogen Inc. 2024 Omnibus Equity Plan. |
| 10.4+* | Form of restricted stock unit award agreement under the Biogen Inc. 2024 Omnibus Equity Plan. |
| 10.5+* | Form of restricted stock unit award agreement for non-employee Director's under the Biogen Inc. 2024 Omnibus Equity Plan. |
| 31.1+ | Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2+ | Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1++ | Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101++ | The following materials from Biogen Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Statements of Income, (ii) the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flow, (v) the Condensed Consolidated Statements of Equity and (vi) Notes to Condensed Consolidated Financial Statements. |
| 104++ | The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, formatted in Inline XBRL. |
- Filed herewith
++ Furnished herewith
- Management contract or compensatory plan or arrangement
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.